Literature DB >> 32369690

Antipsychotic Polypharmacy in Schizophrenia: Why Not?

Daniel Guinart1,2,3, Christoph U Correll4,1,2,3,5.   

Abstract

Entities:  

Year:  2020        PMID： 32369690     DOI： 10.4088/JCP.19ac13118

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


× No keyword cloud information.
  3 in total

Review 1.  Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel.

Authors:  Andrea Fagiolini; José Ángel Alcalá; Thomas Aubel; Wojciech Bienkiewicz; Mats Magnus Knut Bogren; Joaquim Gago; Giancarlo Cerveri; Michael Colla; Francisco Collazos Sanchez; Alessandro Cuomo; Frieling Helge; Eduardo Iacoponi; Per-Axel Karlsson; Pradeep Peddu; Mauro Pettorruso; Henrique Jorge Ramos Pereira; Johan Sahlsten Schölin; Ingo Bernd Vernaleken
Journal:  Ann Gen Psychiatry       Date:  2020-09-26       Impact factor: 3.455

2.  Gender Differences of Schizophrenia Patients With and Without Depressive Symptoms in Clinical Characteristics.

Authors:  Ruimei Liu; Xinyu Fang; Lingfang Yu; Dandan Wang; Zenan Wu; Chaoyue Guo; Xinyue Teng; Juanjuan Ren; Chen Zhang
Journal:  Front Psychiatry       Date:  2022-01-13       Impact factor: 4.157

3.  Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe.

Authors:  Christoph U Correll; Paolo Fusar-Poli; Stefan Leucht; Anne Karow; Nadja Maric; Carmen Moreno; Merete Nordentoft; Andrea Raballo
Journal:  Neuropsychiatr Dis Treat       Date:  2022-02-09       Impact factor: 2.570
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.